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INTRODUCTION
Acute cholangitis, is an infection of the biliary system with a wide spectrum of 
clinical presentations. In its most severe form, it is life threatening and associated with 
significant morbidity and mortality (1).
Stone in the CBD is the most common cause of acute cholangitis. Other causes of 
cholangitis  are  neoplasm,  benign  strictures,  parasitic  infections,  post  operative 
conditions  like  sump  syndrome  and  post  choledochoduodenostomy  and  congenital 
anomalies of the bile ducts(1).
In patients with bacterial cholangitis, bacteremia is seen in 1/3rd of blood cultures 
(2) . Over two-thirds of the bile cultures show mixed infection of two or more organisms 
(3). Empiric broad- spectrum antibiotics and prompt biliary decompression, the mainstay 
of therapy (4) significantly improves outcomes (5).
There is no study from India which compares  etiology, microbiological profile, 
interventions and outcomes in patients with acute cholangitis  from different  regions of 
the country.  There is also no Indian data evaluating anaerobic cultures  (blood / bile) in 
patients with acute cholangitis.

Aims and Objectives of the study
1) To study the  etiological profile, clinical features, interventions and outcomes in 
patients with acute cholangitis from different regions of the country
2) To  study  the  bacteriological  profile  (aerobic  and  anaerobic)  and  antibiotic 
sensitivity in a subset of prospectively enrolled patients with acute cholangitis.
REVIEW OF LITERATURE
DEFINITION:
Acute cholangitis  is  a clinical syndrome with a wide spectrum of presentation 
ranging in severity from a mild form with fever and jaundice, to a severe form with 
septic shock, that develops as a result of stasis and infection in the biliary tract (1).
ETIOLOGY & PREDISPOSING FACTORS:
In approximately 85% of cases, cholangitis is caused by an impacted stone in the 
CBD, with resulting bile stasis (8).  Other causes of cholangitis are neoplasm, benign 
strictures,  parasitic  infections,  post  operative  status  like  sump  syndrome,  post 
choledochoduodenostomy   and  congenital  anomalies  of  the  bile  ducts  (1).   Foreign 
bodies, such as blocked biliary endoprosthesis and surgical sutures, may also lead to 
acute  cholangitis  (4).   Acute  cholangitis  may  also  be  a  complication  from  direct 
cholangiography  due  to  failed  drainage  procedures  in  patients  with  malignant 
obstructive jaundice (4). 
A series from GB Panth Hospital, New Delhi, reported 175 patients of cholangitis, 
of whom 138 had benign causes (122 had CBD stone) and 37 had malignant causes of 
biliary obstruction (9).  Another  series  on cholangitis  reported that  two third of their 
patients had obstruction caused by stones or benign strictures (10).
PATHOGENESIS :
Mechanism of bacterial entry into the biliary tract :
Acute  cholangitis  is  caused  primarily  by  bacterial  infection.  The  organisms 
typically ascend from the duodenum; hematogenous spread from the portal vein is a rare 
source of infection (11).
The sphincter of Oddi normally forms an effective mechanical barrier to duodenal 
reflux and ascending bacterial infection. The continuous flushing action of bile plus the 
bacteriostatic activity of bile salts also help to maintain bile sterility.  Secretory IgA and 
biliary mucous function as antiadherent factors, preventing bacterial colonization (4).
When  the  barrier  mechanism  is  disrupted,  as  occurs  after  endoscopic 
sphincterotomy, choledochal surgery, or biliary stent insertion, pathogenic bacteria enter 
the biliary system at high concentrations.  Thus,  cholangitis  frequently  develops after 
endoscopic or percutaneous manipulation with incomplete biliary drainage or as a late 
complication of stent blockage.
Bacteria  can  also  pass  spontaneously  through  the  sphincter  of  Oddi  in  small 
numbers.  The presence of a foreign body, such as a stone or stent, can then act as a 
nidus for bacterial colonization.  The nutrient rich bile serves as a good culture medium 
for bacteria to multiply (13). 
Bile duct obstruction is necessary, but not sufficient to cause cholangitis.  Chronic 
biliary obstruction raises the intrabiliary pressure, a central pathogenetic event in the 
development of acute cholangitis. High pressure promotes the migration of bacteria from 
the portal circulation into the biliary tract and subsequent colonization. It also favors 
migration  of  bacteria  from  bile  into  the  systemic  circulation,  resulting  in  a  higher 
incidence of septicemia (11).
Bacteriology:
In normal patients, the gallbladder and biliary tree are sterile (15).  In patients 
with bacterial cholangitis, culture of bile is positive in over 90 percent of cases, yielding 
a mixed growth of gram negative and gram positive bacteria. The most common bacteria 
isolated are of enteric origin (14).
• Escherichia coli is the major gram negative bacterium isolated (25 to 50 percent), 
followed  by  Klebsiella  (15  to  20  percent)  and  Enterobacter  species  (5  to  10 
percent) (55). 
• The most  common gram positive  bacteria  are  Enterococcus  species  (10 to  20 
percent) (16). 
• Anaerobes,  such as Bacteroides and Clostridia,  are usually  present  as a mixed 
infection. They are rarely the sole infecting organisms and it is not clear if they 
play  a  role  in  acute  cholangitis.  Recovery  of  anaerobes  appears  to  be  more 
common after repeated infections or surgery on the biliary tree (16). 
A study from Hong Kong analysed the bile and the blood cultures of 579 patients 
with  cholangitis  who presented  over  a  7  year  period  (3).   The  blood cultures  were 
positive in 21% of patients and almost always yielded a single organism,predominantly 
E coli.In contrast, over two-thirds of the bile cultures showed mixed infection of two or 
more  organisms.   Two- third of  the patients  with bacteremia  had similar  organisms 
isolated from blood and bile.  E.coli, Klebsiella, Enterococcus, and streptococcus were 
the most commonly isolated bacteria.
Anaerobic organisms, most commonly Bacteroides were found in 2% of  positive 
bile  cultures  in  elderly  patients  and in  patients  who had  iatrogenic  cholangitis  (3). 
Anaerobic bacteria are usually isolated in conjuction with aerobic bacteria, rather than as 
sole  isolates  from  bile  (52).  Anaerobes  tend  to  be  associated  with  a  more  severe 
infection (29). Candida albicans is the most common fungal cause of cholangitis, usually 
seen  in   immunocompromised  patients  (3).  Case  reports  of  cholangitis  due  to 
Aspergillus and Blastomyces suggests that fungal infection of biliary tree (17) need to 
be  considered  in  the  differential  diagnosis  of  biliary  tract  disease  in  elderly  and 
immunocompromised patients (18). 
A  retrospective  study  of  1394  patients  with  biliary  tract  diseases  from Korea 
showed that gram negative bacteria were the most common organisms cultured in 74% 
of patients.   E coli (36%) and klebsiella (15%) were most commonly isolated followed 
by gram positive bacteria (15%) such as Enterococcus (6%), staphylococcus (3%) and 
streptococcus (2%). Bacteroids were isolated in 5% of patients (19).
Another retrospective study from USA, evaluated patients with cholangitis with 
(Group 1) or without (Group 2) plastic biliary endoprosthesis.  Bile culture were positive 
in 55% of Group 1 and 98% of Group 2 patients. E coli (17%) was the most common 
organism in Group 1 and Enterococcus (31%) most common in Group 2. Bacteremia 
was more common in Group 2 (46% vs 21%). Ciprofloxacillin and Ceftriaxone were the 
most  effective  antibiotics  against  gram  negative  bacilli,  and  Vancomycin  against 
Enterococcus (20).
A study from Seth GS Medical College and KEM Hospital, Mumbai evaluated the 
bacterial profile from duodenum and biliary tree in patients with cholangitis.  Bactobilia 
was found in 83.3%, E coli being the most frequently isolated organism.  63.2% of the 
bacterial strains from the common bile duct and gall bladder were similar to those from 
duodenum (21).
A study from Amrita Institute of medical Sciences, Kerala studied the aerobic 
bacterial  isolates  from  choledochal  bile  in  patients  with  biliary  tract  disease. 
Predominant aerobic bacterial isolates obtained were E coli (30%), Klebsiella (23.98%) 
and Enterococcus (12.21%). Multidrug resistance was noted in 57%.  High resistance 
rates  to  antibiotics  were  observed  for  Gram negative  bacilli  to  ampicillin  (92.4%), 
ciprofloxacin (68.42%), piperacillin (64.33%).  Sensitivity to meropenam was 90.64% 
and amikacin was 76.61%.  Gram positive bacteria were sensitive to ampicillin (86.5%) 
and penicillin (81.4%).  Vancomycin and teicoplanin showed 100% sensitivity (22).
Malini et al from V M Medical college & Safdarjung Hospital, New Delhi studied 
the  microflora  of  bile  aspirates  in  patients  with  acute  cholecysitis  with  or  without 
cholelithiasis.  The most common organisms isolated were E.coli (29.7%), Klebsiella 
(27%),  Salmonella  (8.1%),  Cytrobacter  (3.8%).  The  majority  of  Enterobacteriaceae 
isolates were susceptible to piperacillin-tazobactum and meropenam. 
A  study  from  Tata  Memorial  Hospital,  Mumbai,  evaluated  bile  cultures  and 
sensitivity patterns in malignant obstructive jaundice.  26% had positive bile culture. 
The most common organisms were E.coli (36.6%), Klebsiella (18.3%), pseudomonas 
(8.3%),  Proteus  vulgaris  (8.3%),  and  coagulase  negative  staphylococci  (8.3%). 
Amikacin,  Gentamycin,  cefotaxime,  ceftazidime,  and  Cefoperazone/salbactum 
combination showed good activity against E coli and Klebsiella infections (24).
Bac et al  from Korea retrospectively studied 212 patients with cholangitis and 
evaluated bile cultures and anti microbial susceptibility.  The overall positive rate of bile 
culture was 71.7%.  The organisms cultured were  E coli (25%), Klebsiella (11.1%), 
Pseudomonas  (11.1%),  and  coagulase  negative  Staphylococcus  (9.7%)  and 
Enterococcus  (3.4%).  Effective  antibiotics  for  gram  negative  organisms  were 
amoxicillin/clavulanic acid, amikacin, imepenam and pipercillin / tazobactum.  Blood 
culture was positive in 31.2% of patients (25).
CLINICAL MANIFESTATIONS :
The clinical presentation of patients of with acute cholangitis can be extremely 
varied. The hallmark of cholangitis is Charcots classical triad, consisting of RUQ pain, 
jaundice, and fever.  The full triad is present in only 70% of patients (12). Confusion and 
hypotension  can  occur  in  patients  with  suppurative  cholangitis,  producing Reynold's 
pentad, which is associated with significant morbidity and mortality (57). Hypotension, 
confusion or lethergy may be the only presenting symptom in elderly patients or those 
on corticosteroids. Septic shock in severe cases can lead to multiorgan failure (16). 
Chills resulting from intermittent bacteremia are prominent in about two third of 
patients, and this can be a clue in an atypical presentation (16).
On physical examination fever is almost universal, occurring in 95% of patients. 
RUQ tenderness is elicited in approximately 90% of patients, but jaundice is clinically 
detectable in only 80% (7).  Profound jaundice suggests a malignant etiology (4).
Chronic  biliary  obstruction  may  give  rise  to  multiple  liver  abscesses,  liver 
atrophy, and eventually secondary biliary cirrhosis (26). The spread of infection into 
portal circulation may lead to pyelephlebites and portal vein thrombosis (4). 
Severity assessment of acute cholangitis - Tokyo Guidelines (7): 
The severity of acute cholangitis can be classified into three grades, mild (grade 
I), moderate (grade II), and severe (grade III), on the basis of two clinical factors, the 
onset of organ dysfunction and the response to the initial medical treatment. “Severe 
(grade III)” acute cholangitis is defined as acute cholangitis accompanied by at least one 
new-onset organ dysfunction. “Moderate (grade II)” acute cholangitis is defined as acute 
cholangitis that is unaccompanied by organ dysfunction, but that does not respond to the 
initial  medical  treatment,  with  no  improvement  in  clinical  manifestations  and/or 
laboratory data. “Mild (grade I)” acute cholangitis is defined as acute cholangitis with no 
organ  dysfunction  and  response  to  the  initial  medical  treatment,  with  clinical 
improvement.
Risk factors that predict mortality. A study from France has identified seven risk 
factors that predict mortality in acute cholangitis:   
1)  age  over  50  years,  2)  female  gender,  3)  associated  liver  abscess,  4)associated 
cirrhosis, 5) cholangitis due to a high grade malignant obstruction, 6) cholangitis after 
percutaneous transhepatic  cholangiography,  and 7) acute renal failure (27) 
Laboratory tests:
Routine laboratory tests typically reveal an elevated white blood cell count with 
neutrophil predominance, and a cholestatic pattern of liver dysfunction  with elevations 
in the serum alkaline phosphatase, gammaglutamyl transpeptidase (GGT), and bilirubin 
(predominantly conjugated) (16).
The WBC count is elevated in 80% of patients.  In many patients who have a 
normal WBC count, examination of the peripheral blood smear reveals a dramatic shift 
to immature neutrophil forms. The serum bilirubin level exceeds 2 mg/dl in 80 % of 
patients (28).   Serum Alkaline phosphatase levels are elevated in more than 90% of 
patients of acute cholangitis (29).
Depending on the degree and duration of biliary obstruction,elevations in serum 
aminotransferases may present in either a cholestatic or a hepatitis fashion. With acute 
gallstone  obstruction  of  the  CBD and sudden biliary  pressure  increase,  the  level  of 
serum  aminotransferases  may  reach  thousands  within  24  to  48  hours,  then  rapidly 
decline to lower values.  Mild hyperamylasemia can be found in 40% of cholangitis 
patients without concomitant pancreatitis (30).
Diagnosis :
Ultrasonography is recommended as the first imaging study in patients suspected 
of having cholangitis to look for CBD dilatation and stones.  Ultrasonography may be 
negative when small stones are present in the bile ducts, or in acute obstruction when the 
bile duct has not had time to dilate (16).
Stones in the CBD are seen  on ultrasound in only 50 % of cases, but can be 
inferred by detection of a  dilated CBD in about 75% of cases (31).
An abdominal CT is an excellent test  for excluding complications of gallstone 
disease, but not a good test for excluding CBD stones.
EUS  is  highly  accurate  for  excluding  or  confirming  stones  in  the  CBD. 
Concordance of EUS with ERCP in diagnosing choledocholithiasis is 95% (28).
ERCP is the recommended test for the diagnosis and therapy in  cholangitis.  The 
ability of ERCP to establish drainage of infected bile under pressure is often life saving. 
Occlusive cholangiography should not be performed in patients with acute suppurative 
cholangitis as it can lead to septicaemia (16).
Magnetic  resonance  cholangiopancreatography  (MRCP)  for  the  evaluation  of 
etiology of cholangitis  is  advised when ERCP is unsuccessful  or  fails  to completely 
delineate ductal abnormalities. In the presence of a dilated CBD, this test has a 90 to 95 
percent concordance with ERCP in diagnosing CBD stones (10).  MRCP has an overall 
sensitivity of 95% and specificity of 94% in all biliary diseases (29).
TREATMENT
Untreated acute cholangitis is fatal. Management begins with early recognition of 
the condition. Empiric broad- spectrum antibiotics and prompt biliary decompression are 
the mainstay of therapy (4).
Other  general  measures  include  fluids  to  maintain  urine  output,  correction  of 
coagulopathy, and frequent monitoring of vital signs for evidence of sepsis (16).
Antibiotics:
In  suspected  cases  of  acute  cholangitis,blood  culture  specimens  are  obtained 
immediately and therapy started with antibiotics effective against the likely causative 
organism ( 32). 
Data on antibiotic sensitivity to common organism seen in bile is conflicting and 
there  is  no  consensus  opinion  regarding  the  best  initial  antibiotic  regimen  for 
cholangitis.  Broad  spectrum  antibiotics  effective  against  E.coli,  Klebsiella  and 
Enterococcus  should  be  started.  In  critically  ill  patients,  antibiotics  effective  against 
Pseudomonas  Bacteriodes  and  Yeast  should  be  considered  (33).   A frequently  used 
combination includes a third generation cephalosporin to cover gram-negative bacilli, 
ampicillin to cover gram-positive cocci and metronidazole to cover anaerobes (4).
Gram negative aerobes are well covered by the  ureidopenicillins, carbapenams, 
fluoroquinolones, aminoglycosides and the third generation cephalosporins (1).   Beta 
lactam-based  therapy  appears  to  be  as  effective  as  treatment  with  ampicillin and 
gentamicin with less toxicity (50). Fluoroquinolones appear to have relatively high rates 
of biliary excretion, and one study found that ciprofloxacin may be as effective as triple 
therapy with ceftazidime, ampicillin and metronidazole (34).
Invitro  activity  of  moxifloxacin  and  pipercillin/salbactum  was  prospectively 
evaluated in 65 consecutive patients with acute cholangitis.  Antibiotic resistances were 
observed in 34.9% of patients for pipercillin/salbactum and in 36.5% for moxifloxacin 
(35). 
Empiric  antibiotic  therapy  for  ascending  cholangitis  should  include  broad-
spectrum  parenteral  antibiotic  until  culture  results  are  available.  Suggested  empiric 
antibiotic regimens are (16).
• Monotherapy  with  a  beta-lactam/beta-lactamase  inhibitor,  such  as  ampicillin-
sulbactam (3 g every six  hours)  OR  piperacillin/  tazobactam (4.5 g every six 
hours) OR t icarcillin-  clavulanate   (3.1 g every four hours) 
• Monotherapy with a carbapenem, such as imipenem (500 mg every six hours) OR 
meropenem (1 g every 8 hours) OR ertapenem (1 g daily
• Metronidazole   (500  mg  IV  every  eight  hours)  PLUS  a  third  generation 
cephalosporin, such as ceftriaxone (1 g IV every 24 hours) 
• Metronidazole  (500  mg  IV  every  eight  hours)  PLUS  a  fluoroquinolone 
(ciprofloxacin 400 mg IV every 12 hours or levofloxacin 500 mg IV daily)
Antimicrobial therapy for acute cholangitis - Tokyo Guidelines (2007) –  (38)
1. Bile/Blood  culture  should  be  performed  at  all  available 
opportunities(recommendation B)
2. In  Moderate  (Grade  II)  or  Severe  (Grade  III)  acute  cholangitis,  antimicrobial 
agents  should  be  administered  for  a  minimum  duration  of  5-7  days 
(recommendation A)
3. In Mild (Grade I ) acute cholangitis,the duration of antimicrobial therapy could be 
shorter (2-3 days) (recommendation A)
4. Biliary penetration should be considered in the selection of antimicrobial agents in 
acute cholangitis (recommendation A)
5. Antimicrobial  drugs  should  be  selected  according  to  the  severity  assessment 
(recommendation A)
6. The  presence  of  biliary  obstruction  may  significantly  influence  the  biliary 
penetration  of  the  antimicrobial.Therefore  patients  with  acute  cholangitis, 
especially those with severe (Grade III) disease, should have immediate biliary 
drainage along with appropriate antimicrobial therapy (recommendation A)
7. Antibacterials  for  Grade I  cholangitis:  First–generation  cephalosporins/  second 
generation cephalosprin/ penicillin /B-lactamase inhibitor
8. Antibacterials for Grade II and Grade III cholangitis:  
First  option  -  Wide  spectrum penicillin/  beta  -  lactamase  inhibitor  (as  single 
agent) 
Third or Fourth generation cephalosporins / Monobactums  +  Metronidazole
Second option - Fluroquinolones+ metronidazole
   -  carbapenams
Regardless  of  initial  drug  regimen,  therapy  should  be  modified  to  reflect 
effectiveness against organism(s) recovered in cultures. In general, antibiotics should be 
continued for seven to ten days, although the duration should be tailored according to 
clinical improvement (6). There is some evidence that once good drainage is established, 
3 days of antibiotic treatment may be sufficient (36).
The patients condition should improve within 6-12 hours, and in most cases the 
infection comes under control within 2-3 days, with defervescence, relief of discomfort 
and a decline in the WBC count (28).
What if the organism is carbapenam resistant? A recent study from China showed 
that Thymosin alpha 1 - and ulinastatin – based immunomodulatory therapy for sepsis 
arising  from  intra-abdominal  infection  due  to  carbapenam-resistant  bacteria  was 
effective in improving organ failure score end survival rate (37). 
Establishment of biliary drainage:
Biliary drainage can be achieved by ERCP, a direct percutaneous approach, or 
open surgical decompression.
 
Endoscopic sphincterotomy with stone extraction and/or stent insertion is now the 
treatment of choice for establishing biliary drainage in acute cholangitis (16). The prime 
objective of an urgent endoscopy is to reduce the biliary pressure effectively by a safe 
and expeditious method, rather than to eliminate the underlying lesion (4).  Endoscopic 
drainage is associated with a significantly lower overall rate of mortality and morbidity 
compared  to  surgical  decompression  (4.7  to  10  percent  versus  10  to  50  percent, 
respectively) (39). 
In patients with underlying coagulopathy, those in whom drainage is inadequate 
due to the presence of large stones, or those who are too ill to leave the intensive care 
unit and undergo the procedure with fluoroscopy, drainage can be achieved by insertion 
of a nasobiliary catheter. This procedure permits active decompression of the CBD by 
aspiration and provides a route for irrigation of the biliary system (40).
An internal stent may be another option.  Its relative disadvantages include 1) a 
tendency to be blocked by viscous pus in the absence of access for irrigation and 2) the 
need for a follow-up endoscopy session to remove the stent (11).  A controlled trial 
suggested  that  an  internal  stent  permitted  adequate  drainage  even  when  performed 
without  a  sphincterotomy  (41).   Nasobiliary  drain  and  biliary  stenting  are  equally 
effective in managing patients of  severe cholangitis (42).
Hui and colleagues randomised 74 patients who had acute cholangitis into one 
group that was treated with ES and stenting and another group that was treated with 
stenting alone.There was no significant  difference in the two groups with respect  to 
success rate for stent insertion, complications, length of hospital stay, or resolution of 
jaundice (44).
Chopra and colleagues from UK, studied 43 high risk patients- elderly or with 
debilitating disease. They were randomised to duct clearance or stent insertion .  At 72 
hours, the group that had stent insertion had a complication rate of 7% and the group 
that underwent ductal clearance had a complication rate of 16% (45).
In  a  study  of  105  patients  with  acute  cholangitis,  who  underwent  emergency 
endoscopy, biliary drainage was successful  in 102 patients and clinical improvement 
was achieved in 99 patients,even though 40% of these patients were in septic shock prior 
to the endoscopic procedure(46).
A study from G B Pant Hospital, New Delhi, studied effectiveness of endoscopic 
biliary drainage for severe acute cholangitis due to malignant and benign diseases. 27of 
43  patients  studied  had  benign  disease.  Patients  received  either  a  nasobiliary 
catheter(n-38) or an indwelling stent (n-5) with or without sphincterotomy for biliary 
drainage.Clinical and biochemical response were similar in both groups (24).
Another study from the same centre described endoscopic management of acute 
cholangitis in elderly patients. There was a higher incidence of severe cholangitis, renal 
failure, hypotension and higher mortality (10%) even after successful biliary drainage 
(9).
Percutaneous drainage can be considered when ERCP is unavailable, unsuccessful 
or contraindicated.Success rate of PTBD ranges from 80- 100 %(24).In most  serises 
urgent percutaneous decompression had morbidity less than 10% and a mortality rate of 
5% (47).
In a non-randomised study comparing percutaneous transhepatic biliary drainage 
with  ERCP in  elderly  patients  with  cholangitis  patients,endoscopic  drainage  yielded 
significantly lower morbidity and mortality (48).
The  result  of  successful  endoscopic  biliary  drainage  is  dramatic  and 
gratifying.The patient  may  feel  an  almost  immediate  amelioration of  pain  when the 
intrabiliary pressure is  reduced.Over the next  24-48 hours,defervescence occurs with 
appropriate antibiotic therapy, along with resolution of delirium  (5).
Role of surgery:
Emergency  surgery  for  acute  cholangitis  has  largely  been  replaced  by 
nonoperative biliary drainage.  Once the acute cholangitis is controlled, patients with 
difficult ductal stones may undergo surgical exploration of the CBD for stone removal. 
Elective surgery carries a very low morbidity and mortality compared with emergency 
surgery.   If  emergent  surgery  is  needed  due  to  failure  of  a  nonsurgical  drainage 
procedure,  choledochotomy  with  placement  of  a  large-bore  T  tube  carries  a  lower 
mortality compared to cholecystectomy with CBD exploration (27)
Prognosis :
With effective antibiotics and biliary drainage, the prognosis for mild to moderate 
cholangitis  is  much  improved.  However,  the  mortality  rate  remains  very  high 
(approximately 50 percent) for patients with severe cholangitis (13).
METHODOLOGY
A) RETROSPECTIVE ANALYSIS OF PATINTS WITH ACUTE 
CHOLANGITIS
Retrospective descriptive study:
Retrospective analysis of patients diagnosed to have Acute Cholangitis attending 
Christian Medical College Hospital,  Vellore during the period from January 2004 to 
December 2008 (5 Years). 
Subjects:
185 patients with Acute Cholangitis were included in the analysis.
Details  of  demographic  data,  etiology  of  biliary  obstruction,  clinical  features, 
biochemical  parameters,  microbiological  spectrum,  interventions  and  outcomes  were 
recorded.
Diagnosis of Acute Cholangitis:
The diagnosis of Acute Cholangitis was based on presence of clinical evidence of 
infection (fever, leucocytosis and abdominal pain) in patients with biliary obstruction 
(1,29,42).   Biliary obstruction was detected by LFT abnormalities  and common bile 
duct/intrahepatic bile duct dilatation on imaging.
Patients were labelled as having severe acute cholangitis if they had features like 
hypotension, impaired level of consciousness or any organ failure (6, 7).
B) PROSPECTIVE ANALYSIS OF PATIENTS WITH ACUTE
CHOLANGIITS
Prospective observational study:
31  patients  with  Acute  Cholangitis  were  prospectively  analysed  for 
Bacteriological profile and Antibiotic Sensitivity during the period from April 2007 to 
December 2008.
Inclusion Criteria :
1. All patients suspected to have cholangitis.
2. Patients more than 18 years of age
Exclusion Criteria:
1. Patient in shock.
2. Antibiotics prior to ERCP
3. ERCP/PTBD not possible.
Protocol:
      All patients with suspected cholangitis had the following:
• Blood sent for Hb, Platelets, TC/DC, LFT, Creatinine, PT, PTT
• Blood for aerobic and anaerobic cultures
• Emergency Ultrasound abdomen
• Emergency  ERCP  was  performed  and  bile  collected  for  both  aerobic  and 
anaerobic cultures.  Bile duct decompression was performed in all patients.
• After  collection  of  bile  of  culture  (5-10ml)  empiric  antibiotic  was  started 
immediately.
• Microbiologists were requested to perform routine and special sensitivity study 
for all cultures.
ANALYSIS:
Details  of  demographic  data,  etiology  of  biliary  obstruction,  clinical  features, 
biochemical  parameters,  microbiological  spectrum and  sensitivity,  interventions  and 
outcomes were recorded and analysed.
CONSENT:
Informed written consent (Annexure I) was taken for all patients included in the 
study.  Written consent was also taken prior to ERCP/PTBD as per department protocol.
STATISTICAL ANALYSIS:
Data was analysed by statistical  software SPSS (Statistical  Package for  Social 
Sciences, release 11.0, standard version; SPSS Inc.).
This was a retrospective and prospective study.  Data was reported as means with 
standard deviation for normally distributed continuous data or median with ranges for 
non  normally  distributed  continuous  data  and  as  frequencies  and  percentages  for 
catageorical variables.
Student-test  was  used  for  normally  distributed continuous  variables  and Mann 
Whitney  test  for  non  normally  distributed  continuous  variables.   For  comparing 
categorical variables chi-square test was used.  A P value of less than or equal to 0.05 
was considered statistically significant.
RESULTS
A total of 185 patients were analysed in the combined group and 31 patients were 
prospectively studied for bacteriological profile and antibiotic sensitivity.
Demographic characteristics and clinical profile of patients is shown in Table 1.
The mean age of patients was 51.3 + 13.4 Years. 102 (55.1%) patients were males 
and rest 83(44.9%) females, the male: female ratio being  1.3:1. 84(45.4%) patients were 
from south and 101(54.6%) patients from the eastern parts  of India, reflecting patient 
profile visiting CMC. 
The frequency of patients with cholangitis over past 5 years is shown in Fig. 1. 
The number of patient /  year (2004: 36; 2005: 33: 2006: 37; 2007: 37; 2008: 42) is 
similar over 5 years.
Figure 1 : Frequency of patients / year with cholangitis
n = number of patients
The most common symptom at presentation was fever( 96.8%). Pain abdomen 
and jaundice were present in 75.7% and 75.1%  of patients respectively. Anorexia and 
weight loss were present in 70.3 % and 57.3% of patients. Seven (3.8%) patients had 
history of melena at presentation.
Past history of biliary colic and jaundice were present in 38.9% and 15.1% of 
patients respectively.  Forty six (24.9%) patients had ERCP for biliary diseases in the 
past.    Twenty  two   (11.9%)  patients  had  history  of  cholecystectomy.   History  of 
diabetes and hypertension were  present in 13.5% and 6.5% of patients respectively. 
Very few patients had history of alcoholism and smoking (5.9% and 3.2% respectively).
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On examination icterus was present in 80.5% of patients.  Seven (3.8%) patients 
had altered sensorium at  presentation.   Signs of  liver  failure  was detected in 7% of 
patients.
Table – 1 : Demographic and clinical profile of patients with cholangitis 
Variables All patients (N-185)
Age (Mean + SD) yrs. 51.3+13.4
Sex (Male),number 102(55.1%)
Region(South/East) 84(45.4%)/101(54.6%)
Fever 179(96.8%)
Pain 140(75.7%)
Jaundice 139(75.1%)
Anorexia 130(70.3%)
Weight loss 106(57.3%)
Cholestatic symptoms 74(40.2%)
GI Bleed 7(3.8%)
Past H/O biliary colic 72(38.9%)
Past H/O ERCP 46(24.9%)
Past H/O Jaundice 28(15.1%)
DM 25(13.5%)
Hypertension 12(6.5%)
Alcohol 11(5.9%)
Smoking 6(3.2%)
Icterus 149(80.5%)
Altered sensorium 7(3.8%)
Signs of Liver Failure 13(7%)
Abdominal tenderness 54(29.2%)
Past H/O Cholecystectomy 22(11.9%)
Imaging findings: (Table 2 )
Of the 185 patients analysed,  170 had US and 33 had MRI abdomen.  IHBRD was 
detected  in 88.2% of patients by  US  and 97.2%  by  MRI abdomen.
The mean CBD diameter on US was 13.3 +  4.9mms.   US detected CBD stone in 55.3% 
of  patients.   On  ERCP 63.9%,  25.7% and  2.8% of  patients  were  detected  to  have 
choledocholothiasis, stricture in CBD and choledochal cyst respectively.
 Table - 2 : Imaging findings in patients with cholangitis
Variables All patients (n = 185)
U/S( N-170) MRI(N-33)
IHBRD , numbers 150(88.2%) 35(97.2%)
Dilated CBD (%) 84.9 88.8
CBD Diameter (mms) Mean+SD) 13.3+4.9 -
Gall stone/sludge , n-169 67(39.6%) -
Stone in CBD (%) 55.3 42.1
Stricture (%) 8.2 22.1
Malignancy (%) 20 36.8
 Laboratory profile (Table 3):
The mean Haemoglobin and serum albumin  were 11.1 + 2.3 gm%  and 3.2 +  0.7 
gm%   respectively.  The  median  serum  bilirubin,  SGOT,  SGPT,  serum  alkaline 
phosphatage were  7.1 mg% ( 0.4-40 ),87.50 U/L(18-500 ),80.50 U/L ( 6-463 ) and 
371.50 U/L ( 59-2511 ) respectively.
The median serum cretinine was 0.9 mg% (0.4-7)
Table – 3 :  Laboratory profile
Laboratory profile All patients (n-185)
Haemoglobin (gm%) (Mean+SD) 11.1+2.4
Total count (cu mm)
(Median&Range)
13800
(2200-80000)
Ser Bilirubin(mg%)
(Median&Range)
7.1
(0.4-40)
Ser Albumin(gm%) (Mean+SD) 3.2+0.7
SGOT(U/L)
(Median&Range)
87.50
(18-500)
SGPT(U/L)
(Median&Range)
80.50
(6-463)
Alkaline phosphatase(U/L)
(Median&Range)
371.50
(59-2511)
Ser Creatinine(mg%)
(Median&Range)
0.90
(0.4-7)
Microbiological profile (Table 4): 
Combined Group (retrospective and prospective group) :  One hundred and 
seventy  eight  patients  had  aerobic  blood culture  prior  to  empiric  antibiotic  therapy. 
Bacteremia was seen in 26.4% of cultures. Most of the cultures grew single organism 
(91.5  %).  E.  coli  was  the  predominant  organism  (70.2%),  followed  by 
Klebsiella(14.9%), Pseudomonas (4.3%) and Enterococcus (2.1%) .
Bile  culture  was done in  88 patients.  Most  (92.6%) of   the   cultures  showed 
growth.  In contrast to blood cultures, most (75%) of the bile cultures grew multiple 
organisms.  E. Coli and Enterococci were the predominant organisms (64.8 and 43.2% 
respectively), followed by Klebsiella (30.7%), Pseudomonas ( 13.6%) and Citrobacter 
(10.2%).
Prospective study group : 
All 31 patients had  blood culture done.  32.3% had bacteremia and most cultures 
(80%) grew a single organism.  E coli was the most common (90%) organism grown, 
followed by klebsiella and Enterococcus (10% each).
All  31  patients  had  aerobic  bile  cultures  and  93.5% of  the  cultures   showed 
growth. Most of the cultures grew multiple organisms (82.8%). E.coli and Enterococci 
were  the  most  common  organisms  grown  (  65.5  %  each),  followed  by  Klebsiella 
(34.5%), Citrobacter (13.8%) and Pseudomonas ( 6.8%).
None of the anaerobic cultures (Blood- 29, Bile – 31) showed any growth.
Table – 4 : Microbiological profile of  patients with cholangitis
Culture/Org
anisms
Combined group(N-185) Prospectively study group(N-31)
Blood 
culture
(Aerobic
n-178)
Blood 
culture
(Anaer
obic 
n-30)
Bile 
culture
(Aerobic
n-95)
Bile 
culture
(Anaer
obic
n-31)
Blood 
culture
(Aerobic 
n-31)
Blood 
culture
(anerob
ic
n-29)
Bile 
culture
(Aerobi
c
n-31)
Bile 
culture(
Anaero
bic
n-31)
Growth 47
(26.4%)
0 88
(92.6%)
0 10
(32.3%)
0 29
(93.5%)
0
Multiple
Organisms
(%)
8.5 - 75% - 20% - 8
(2.8%)
-
E.Coli 34
(72.3%)
- 57
(64.8%)
- 9
(90%)
- 19
(65.5%)
-
Klebs
Sp
7
(14.9%)
- 27
(30.7%)
- 1(10%) - 10
(34.5%)
-
Pseudo
monas
 
2(4.3%) - 12
(13.6%)
- 0 - 2
(6.8%)
-
Citrobacter 0 - 9
(10.2%)
- 0 - 4
(13.8%)
-
Enterococcus 1(2.1%) - 38
(43.2%)
- 1(10%) - 19
(65.5%)
-
α- Hemostep 0 - 2
(2.3%)
- 0 - 1
(3.4%)
-
Comparision of  microbiological  profile in retrospective and prospective  groups 
(Table 5): 
147  blood  cultures  and  64  bile  cultures  were  analysed  in  the  retrospective 
group( Group- 1) and 31 blood and bile cultures were analysed in the prospective group( 
Group  –  2).   Microbial  profile  in  prospective  study  group  was  similar  to  the 
retrospectively studied group of patients.
Table  –  5  Comparison  of  the  microbial  profile  between  retrospective  and 
prospective study groups
Bacteriological 
profile and
sensitivity
Blood cultures Bile cultures
Group-1 
(n-147)
Group-2 
(n-31)
p- 
value
Group-1 
(n-64)
Group-2 
(n-31)
P-value
Growth 37
(25.2%)
10
(32.3%)
0.5 59
(92.2%),
29
(93.5%)
1
Multiple organisms 1
(2.7%)
2
(20%)
0.08 47
(73.4%)
24
(82.8%)
0.8
E. coli 23
(62.2%)
9
(90%)
0.1 37
(62.7%)
19
(65.5%)
0.83
Klebsiella sp 5
(13.5%)
1
(10%)
1 14
(23.7%)
10
(34.5%)
0.3
Pseudomonas sp 2
(6.4%)
0 1 8
(13.6%)
2
(6.8%)
0.5
Antibiotic sensitivity: 
Bile cultures (Table 6)
All  31  patients  had  bile  culture.   The  sensitivity  of  E  coli  to  Imipenam and 
Meropenam  was  100%  followed  by  Netilmicin  (88.2%),  Amikacin  (78.9%), 
Piperacillin  /  Tazobactum  (56.4%),  Gentamycin  (45%),  Cefoperazone/salbactum 
(39.6%),  Ticarcillin  /  clavulinic  acid  (38.8%),  Ceftazidime  (21.1%),  Cefotaxime 
(16.7%), Ampicillin (16.7%) and Ciprofloxacin (14.3%).
The  sensitivity  of  Klebsiella  to  Imipenam and Meropenam was  100%,  followed  by 
Amikacin (72.7%), Netilmicin (66.7%), Piperacillin / Tazobactum (52.4%), Gentamycin 
(36.3%),  Cefoperazone  /  salbactum  (41.2%),  Ticarcillin  /  clavulinic  acid  (36.8%), 
Ceftazidime (18.2%), Ciprofloxacin (18.2%), Ampicillin (16.7%), Cefotaxime  (10.5%).
The sensitivity of Pseudomonas  to Imipenam and Meropenam was 100%, followed by 
Piperacillin  /  tazobactum  (68.7%),  Cefoperazone  /  salbactum  (68.7%),  Amikacin 
(66.7%), Netilmicin (66.7%), Ticarcillin / clavulinic acid (66.7%), Ceftazidime (66.7%), 
Ciprofloxacin (66.7%), Gentamycin (50%).
The  sensitivity  of  Enterococci  was  94.7%  to  Teicoplanin  and  Vancomycin, 
followed  by  Ampicillin  (84.2%),  high  dose  gentamycin  (78.9%)  and  Ciprofloxacin 
(26.3%).
Table – 6  Bile culture and sensitivity of prospective study enrolled patients with 
cholangitis
Antibiotics E.Coli 
(%)
Klebsiella sp 
(%)
Pseudomonas sp 
(%)
Enterococcus
(%)
Amikacin 78.9 72.7 66.7 -
Cefotaxime 16.7 10.5 - -
Ticar/Clavul 38.8 36.8 66.7 -
Cefoper/Salbact 39.6 41.2 68.7 -
Ceftzidime 21.1 18.2 66.7 -
Gentamycin 45 36.3 50 -
Netilmicin 88.2 66.7 66.7 -
Piper/ Tazobac 56.4 52.4 68.7 -
Ciprofloxacin 14.3 18.2 66.7 26.3
Ampicillin 16.7 16.7 ND 84.2
Imipenam 100 100 100 -
High dose gent-
amycin
- - - 78.9
Teicoplanin - - - 94.7
Vancomycin - - - 94.7
Blood culture and sensitivity (Table 7): 
All 31 patients had blood culture.   The sensitivity  of E coli  to Imipenam and 
Meropenam was 100%, followed by Netilmicin (85.7%), Amikacin (62.5%), Piperacillin 
/  tazobactum  (57.1%),  Gentamycin  (37.5%),  ciprofloxacin  (37.5%),  Ticarcillin  / 
clavulinic  acid  (33.4%),  Cefoperazone  /  salbactum  (28.6%),  Ceftazidime  (25%), 
Ampicillin (25.7%), Cefotaxime (25%).
The  sensitivity  of  Enterococcus  was  100%  to  Teicoplanin  and  Vancomycin, 
Ampicillin and high dose gentamycin.  The organism was resistant to ciprofloxacin.
Table - 7 : Blood culture and sensitivity of prospective study 
patients with cholangitis
Antibiotics E.Coli (%) Enterococcus (%)
Amikacin 62.5 -
Cefotaxime 25 -
Ticar/Clavul 33.4 -
Cefoper/Salbac 28.6 -
Ceftazidime 25 -
Gentamycin 37.5 -
Netilmicin 85.7 -
Piper/Tazobac 57.1 -
Ciprofloxacin 37.5 0
Ampicillin 25.7 100
Imipenam 100 -
High dose gentamycin - 100
Teicoplanin - 100
Vancomycin - 100
Etiological profile and Intervention (Table 8): 
Stone disease (Choledocholithiasis) was the most common (61.6%) etiology in 
patients of cholangitis, followed by malignancy(29.7%) and benign stricture (9.2%).
Nasobiliary drainage (NBD) was  performed in 53 (28.7%) patients and biliary 
stenting in 55(29.7%) patients. Stone clearance of CBD was performed in 26(14.1%) 
patients. In 15(8.1%) patients percutaneous trans-hepatic biliary drainage (PTBD) was 
done as ERCP was not feasible or unsuccessful.   Thirty- four (18.4%) patients were 
treated with antibiotics alone.
 Table - 8 : Etiological profile and Intervention
Etiology &  Intervention All patients  (n-185)
Stone disease 114(61.6%)
Benign stricture 17(9.2%)
Malignancy 54(29.2%)
NBD 53(28.6%)
Biliary stenting 55(29.7%)
Stone clearance 26(14.1%)
PTBD 15(8.1%)
Antibiotics alone 34(18.4%)
Comparison of microbiological profile and outcome between  benign and malignant 
obstruction (Table 9): 
Benign and malignant etiologies were found in 129 and 56 patients respectively.  
Benign group: The mean age was 51.5 +  13.8 years.67 ( 51.9%) patients were male. 
Out of 67 bile cultures, 63(94.1%) showed bacterobilia.   Most of the cultures (68.3%) 
grew multiple  organisms.   E.  coli  was  the  most  common organism (66.7%)  grown, 
followed by Enterococcus (44.4%), Klebsiella (26.9%) and Pseudomonas (11.1%).
NBD was performed in 38 (30.2%) patients and biliary stenting in  35(27.1%) 
patients. Six (4.7%) patients had PTBD. Twenty one ( 16.3%) patients did not have any 
intervention and were treated with antibiotics alone.   One hundred and twenty three 
(91.9%) patients were stable at discharge. Eight (6.5%) patients died during treatment.  
Malignancy Group: The mean age was 51+ 12.7 years.  35(62.5%) patients were male. 
Out of 28 bile cultures, 25(89.3%) were positive and mostly with  multiple organisms 
(64%). E coli  was the most common organism(56%) grown, followed by Enterococcus 
(40%), Klebsiella (12%) and Pseudomonas (12%).
NBD was done in 12 (21.4%) patients and biliary stenting  in 20(35.7%) patients. 
Nine  (16.1%)  patients  had  PTBD.   Thirty-five  (74.5%)  of  patients  were  stable  at 
discharge.  Two (4.2%) patients died during treatment.  Except PTBD which was done 
more often in Malignant group, other variables were similar between the two groups.
Table – 9 : Microbiological profile, intervention and outcome between benign and 
malignant groups
Microbiological 
profile,sensitivity,
Intervention and outcome
Benign Gr
(n-129)
Malignant Gr
(n-56)
P-value
Age(Mean+SD) 51.45+13.808 51+12.676 0.8
Sex(Male) 67(51.9%) 35(62.5%) 0.2
Growth in bile culture* 63(94.1%) 25(89.3%) 0.42
Multiple organisms 43(68.3%) 16(64%) 0.6
E. coli 42 (66.7%) 14 (56%) 0.3
Klebsiella 17 (26.9%)  3 (12%) 0.17
Pseudomonas   7 (11.1%)  3 (12%)      1
Enterococcus 28 (44.4%) 10 (40%) 0.65
NBD 38(30.2%) 12(21.4%) 0.3
CBD stenting 35(27.1%) 20(35.7%) 0.3
PTBD 6(4.7%) 9(16.1%) 0.02
Antibiotics alone 21(16.3%) 15(26.8%) 0.1
Death 8(6.5%) 2(4.2%) 0.73
* Bile culture: Benign group: 67, Malignant group: 28
Comparison  of  etiological  and microbiological  profile  and outcomes  in  patients 
from different  regions of the country ( Table 10 ):
CMC being a tertiary care referral hospital, patients come from different parts of 
India for treatment.  84 patients were from southern region (SR) and 101 from eastern 
region (ER).
Southern region: The mean age was 53.3+ 14.5 years.  52(61.9%) patients were male. 
Stone disease (choledocholithiasis) was the most common etiology (76.2%), followed by 
malignancy(19.1%) and benign stricture (4.7%). Out of 37 bile cultures performed, 34 
(91.9%) were positive with multiple organisms in 67.7% of cultures. E coli was the most 
common  organism  grown  (55.8%),  followed  by  Enterococcus  (52.9%),  Klebsiella 
(35.3%) and Pseudomonas (2.9%).  NBD was done in 25 (29.8%) of patients and biliary 
stenting in 28 (33.3%) patients.  Six (7.1%) patients had PTBD.  Seventy-four (90.5%) 
of patients were stable at discharge.  Four (5.4%) patients died during treatment.  
Eastern region: The mean age was 49.7 + 12.3 years.  50 (49.5%) patients were male. 
Stone disease (choledocholithiasis) was  the most common (48.5%) etiology, followed 
by malignancy (37.6%) and benign stricture(13.8%). Out of 58 bile cultures performed, 
54 (93.1%) were positive, with 42 (72.4%) of cultures showing multiple organisms. E 
coli  was the most common organism grown (66.7%), followed by Enterococci (38.9%), 
Klebsiella (18.5%) and Pseudomonas (12.9%).
NBD was done in  26(25.7%) of  patients  and biliary stenting in 27(26.7%) of 
patients.Nine (8.9%) patients had PTBD.  Eighty-one (84.4%) of patients were stable at 
discharge.Six  (6.2%)  patients  died  during  treatment.  Stone  disease  was  found  to  be 
significantly more common in patients from southern region and malignancy in Eastern 
region. There was no difference in the microbiological profile and outcome between 
patients from Southern and Eastern region of India.
Table  –  10  Etiology,microbiological  profile, interventions  and  outcomes  in  two 
region groups
Etiology,microbiological 
profile,intervention  and 
outcomes
Group 1 
(south)
(n-84)
Group 2 (East)
(n- 101)
P- value
Age(Mean+SD) 53.3+14.5 49.7+12.3 0.08
Sex(Male) 52(61.9%) 50(49.5%) 0.1
Stone disease 64(76.2%) 49(48.5%) <0.001
Malignancy 16(19.1%) 38(37.6%) 0.05
Growth in bile culture* 34(91.9%) 54(93.1%) 1
Multiple organisms 26(67.6%) 42(72.4%) 0.8
E. coli 19(55.8%) 36(66.7%) 0.4
Klebsiella sp 12(35.3%) 10(18.5%) 0.13
Pseudomonas 1(2.9%) 7(12.9%) 0.14
Enterococcus 18(52.9%) 21(38.9%) 0.29
NBD 25(29.8%) 26(25.7%) 0.6
CBD stenting 28(33.3%) 27(26.7%) 0.34
PTBD 6(7.1%) 9(8.9%) 0.8
Death 4(5.4%) 6(6.2%) 1
*  Bile culture performed: Group 1: 37; Group 2: 58
Comparison of etiology and outcome  in  NBD( NBDG) and stenting (SG) groups 
(Table 11): 
NBD was done in 51 patients and biliary stenting in 55 patients.
NBD  Group:  The  most  common  etiology  was  stone  disease  (72.5%),  followed  by 
malignancy (23.6%) and benign stricture (3.9%).  None of the patients had any post 
procedure complication. None of them required repeat procedure.  Forty-four (95.6%) 
patients were stable at discharge.One (2.2%) patient died during treatment.  The mean 
duration of hospital stay was 8.6 days.
Stent  Group: The  most  common  etiology  was  stone  disease  (56.9%),  followed  by 
malignancy (32.7%) and benign stricture (3.6%).
One  patient  had  mild pancreatitis  after  biliary stenting,  which was managed 
conservatively.   Another  patient  did  not  improve  with  biliary  stenting  and  required 
NBD.  Fifty-four (81.5%) patients were stable at discharge.  One (1.8%) patient died 
during treatment. The mean duration of hospital stay was 6.6 days.
There was no difference between the NBD and stenting groups with regard to 
technical success and outcome.  Both procedures were found to be equally effective.
Table -11 : Etiology and outcome between NBD and Stenting groups
Etiology and
outcome
NBD Group
(n-51)
Stenting 
Group
(n-55)
P- value
Stone disease 37(72.5%) 31(56.9%) 0.1
Benign stricture 6(3.9%) 2(3.6%) 0.15
Malignancy 12(23.6%) 18(32.7%) 0.4
Complication 0 1(1.8%)* 1
Rpt procedure 0 1(1.8%)** 1
Stable at
discharge
n-46
44(95.6%)
n-54
44(81.5%)
1
Duration of 8.57 6.6 0.064
hospital stay  (mean)
* Mild pancreatitis
** 1 patient had NBD after stenting
Factors predicting  mortality ( Table – 12 ): 
147 patients were stable at discharge and 10 patients died during treatment.
Multiple factors were analysed between patients who were stable at discharge and 
those who died during treatment to predict mortality.  In Univariate analysis, sensorium 
at  admission,  ICU care,  serum bilirubin, systolic blood pressure and pulse rate were 
found to be significant factors  in predicting mortality. After multivariate analysis only 
ICU care was found to have significant association with mortality.
Table - 12 : Factors that predicts mortality
Variables Univariate analysis        
                                              P- value
  Alive             Dead
Multivariate 
analysis
P- value
Sensorium 1/147 3/10 0.001 0.17
ICU care 0/147 3/10 <0.001 0.001
Bilirubin 6.5(1-37) 11.6(5-19) 0.012 0.401
BP systolic 114.7(10.3) 97(10.6) <0.001 0.06
Pulse 89.5(12.1) 108.4(15) 0.003 0.83
DISCUSSION
The current study is a retrospective analysis of etiological factors, microbiological 
profile, interventions and outcomes in 185 patients  diagnosed to have acute cholangitis 
over a 5 year period.  As the microbial profile and antibiotic sensitivity changes over 
time, we prospectively  analysed the bacteriological profile (aerobic and anaerobic) 
and antibiotic sensitivity in 31 patients with acute cholangitis.
DEMOGRAPHY:
The mean age of patients was 51 years and the male:  female ratio was 1.3:1. 
Similar findings were observed in earlier studies (23).   Majority of patients (54.6%) 
were  from  eastern  region,  reflecting  the  profile  of  patients  seeking  health  care  at 
Christian Medical College. Clinical presentation of patients in the present study (fever: 
97%; Abdominal pain: 76%, Jaundice: 75%) were similar to previous studies (4,28). 
Pamela  et  al  (1)  showed  that  around  5%  of  patients  present  with  severe  acute 
cholangitis. In our study 3.8% presented with altered sensorium  suggestive of severe 
cholangitis.
Imaging studies:
Previous studies have shown that, the sensitivity of US in detecting stones in CBD 
is only about 50 %.  However, biliary obstruction can be inferred by detection of a 
dilated biliary system in about 75% of cases (31). In the present study, US detected CBD 
stone in 55.3% of patients, IHBRD in 85% and MRI in 89% of patients.
Laboratory profile: 
Laboratory tests typically reveal leucocytosis with shift to left  and  cholestatic 
pattern of liver function (16).  Elevated WBC count and serum
bilirubin  more  than  2  mg/dl  is   seen  in  80  % of  patients  (28)  .   Serum  Alkaline 
phosphatase levels are elevated in more than 90% of patients with acute cholangitis (29). 
In this study, the median total peripheral  count was  13800 /cmm (range 2200-80000), 
the median serum Bilirubin and alkaline- phosphatase were 7.1 mg%  ( 0.4-40 ) and 372 
U/L (59- 2511) respectively. Laboratory findings in the present study were similar to the 
previous studies.
Etiological profile :
A series from Delhi,  reported stone disease to be the most common cause of 
biliary obstruction, followed by malignancy in patients of acute cholangitis (9).  Boey 
JH et al in a series from the West also reported stone disease as the predominant cause 
of biliary obstruction (10).  Results from the present study is similar to other studies. 
Choledocholithiasis is the most common cause (62%) followed by malignant obstruction 
(30%) and benign bile duct stricture (9%).
 
Microbiological profile: 
Numerous studies from India and West showed positive blood culture in 20-30% 
and positive bile cultures in 70- 90% of patients.  A single organism was commonly 
grown in blood cultures and multiple organisms in bile cultures.  The most common 
gram negative bacteria grown was E coli and gram positive bacteria was Enterococcus 
(16, 3, 2, 19, 21, 22, 23, 24, 25).  Microbial profile of blood and bile cultures in the 
present study is similar to previous studies. In the present study bacteremia was seen in 
26.4% of blood cultures.  Most blood cultures grew single organism (91.5 %). E. coli 
was the predominant organism (70.2%), followed by Klebsiella (14.9%), Pseudomonas 
(4.3%) and Enterococcus (2.1%). Bacterobilia was seen in 92.6% of bile cultures. Most 
(75%)  of  the  bile  cultures  grew multiple  organisms.    E.coli  was  the  predominant 
organism  (64.8%),  followed  by  Enterococcus  (43.2%)  Klebsiella  (30.7%)  and 
Pseudomonas (13.6%).  
Leung JW et al reported anaerobic growth, predominantly Bacteroides in 2% of 
bile cultures in elderly patients and patients with iatrogenic cholangitis (3). Chang WT et 
al, in a retrospective study of 1394 patients with  biliary treact diseases, found  anaerobic 
infection   in  5% of  the  patients  (19).  There  is  no  Indian  data  regarding  anaerobic 
infection in patients with  acute cholangitis.  None of the blood (n =29) or bile cultures 
(n=31) done  in patients with acute cholangitis in the present study showed anaerobic 
infection.  Larger number of patients need to be studied to opine about frequency of 
anaerobic infections in patients with acute cholangitis. 
 Comparison  of   the  microbiological  profile  in  blood   and  bile   between 
retrospective(154  patients)  and  prospective  groups  (31  patients)   showed  no  major 
change suggesting that the microbial profile is constant over a period of 5 years.
Antibiotic sensitivity profile in prospective study group:
Studies in the past (both Indian and Western) showed gram negative organisms 
were sensitive  to  Cefotaxime,  Ceftazidime,  Ciprofloxacin,  Cefoperazone  /  salbactum 
and gram positive organisms to Ampicillin and ciprofloxacin (20, 24).  In the present 
study, the gram negative bacteria in a majority of patients were resistant to Cefotaxime, 
Ceftazidime, Ciprofloxacin, Ampicillin, Cefoperazone-salbactum, Ticarcillin-clavulinic 
acid, the common antibiotics recommended as empiric therapy for patients with acute 
cholangitis.   These organisms in  the majority  of  patients  were however  sensitive  to 
Carbapenams, Netilmicin, Amikacin and Piperacillin/tazobactum in  decreasing order of 
sensitivity.  Gram positive  organisms were resistant  to  ciprofloxacin  and sensitive  to 
ampicillin, vancomycin, Teicoplanin and high dose gentamycin.  Antibiotic sensitivity 
profile in the present study is similar to two recent Indian studies, from Kerala, and New 
Delhi (22, 23).   These results suggest that there is a need for fresh recommendation on 
empiric antibiotic therapy for cholangitis.
Interventions:
Nasobiliary drainage (NBD) was performed on 51 patients and bile 
duct stenting on 55 patients.  The technical success rate and outcome were compared 
between NBD and stenting groups. No significant difference was found between the two 
groups. This is similar to a study from New- Delhi which showed, Nasobiliary drain and 
biliary stenting were equally effective in managing patients of  severe cholangitis (42). 
Microbiological profile, intervention and outcome between benign and malignant 
groups:
The microbiological profile and outcomes were similar in both groups of patients. 
As expected PTBD was performed more often in patients with malignant obstruction. 
This result is similar to a study from 
New Delhi, where the outcome was similar between malignant and benign groups (24). 
Another study from Mumbai, showed similar microbiological profile in patients with 
benign and malignant biliary obstruction (23). 
Etiology,  microbiological  profile,  interventions  and  outcomes  in  patients  from 
different regions:
There  is  no  study  in  Indian  patients  with  acute  cholangitis  which  compared 
patients from different regions of the country.  In our study, stone disease was more 
common in patients from southern regions and malignant biliary obstruction in patients 
from eastern regions. The reason for the difference in etiology of obstruction between 
two regions, may be because sick  patients with malignancy travel south to a tertiary 
centre while those with benign stone disease are treated at local hospitals close to home. 
The microbiological profile interventions and outcomes were not different between two 
groups.
Factors that predicts mortality : 
In a multivariate analysis from France (27), seven risk factors were identified to 
predict the mortality in acute cholangitis: 1) age over 50 years, 2) female gender, 3) 
associated liver abscess, 4) associated cirrhosis,  5) cholangitis due to  a  high grade 
malignant   obstruction,       6)  cholangitis  after  percutaneous  transhepatic 
choledochography, and 7) acute renal failure.   
In the present study, multiple factors were analysed between patients who were 
stable  at  discharge  and  those  who  died  during  treatment  to  predict  mortality.   In 
Univariate analysis,  sensorium at admission, ICU care, serum bilirubin, systolic blood 
pressure  and pulse  rate  were  found  to  be  significant  in  predicting  mortality.   After 
multivariate  analysis  only  ICU care  was  found  to  have  significant  association  with 
mortality.
CONCLUSIONS
1. The  most common cause of biliary obstruction in patients with acute cholangitis 
is  stone  disease  (Choledocholithiasis).   Malignant  disease  is  responsible  for 
obstruction in 1/3 of patients. 
2. Ultrasound examination of abdomen is an effective, inexpensive and non-invasive 
test  for  diagnosis  of  biliary  obstruction.   It  should  be  the  initial  imaging  test 
performed in patients with acute cholangitis.
3. Bacteremia with single organisms (Gram negative) is seen  in 1/3rd of  patients 
with acute cholangitis, Gram positive organisms are rare in blood cultures. 
4. More than 90% of bile cultures show  positive growth  with  multiple organisms 
in  2/3rd of the cultures. Most common  organisms are E.coli and Enterococcus, 
followed by  Klebsiella and Pseudomonas.
5. The  bacteriological  profile  has  not  changed  over  time.  It  is  the  same  in  our 
patients over the past 5 years.
6. Anaerobic bacteria were not grown in bile or blood in the present study. Large 
numbers of patients need to be studied to opine about frequency of anaerobic 
infection in Indian patients.
7. Gram negative bacteria are resistant in a majority of patients to the commonly 
recommended  antibiotics  like  cefotaxime,  Ceftazidime,   Ciprofloxacin, 
Ampicillin,  Cefoperazone-salbactum and  Ticarcillin-clavulanic  acid.  They  are 
sensitive  to  Imipenam,  Meropenam,  Netilmicin,  Amikacin,  and  Piperacillin  / 
Tazobactum  in  decreasing  order  of  sensitivity.  Gram  positive  bacteria  are 
sensitive to Vancomycin, Teicoplanin, high dose Gentamycin and Ampicillin in 
the decreasing order of sensitivity.
8. There is a need for change in strategy for empiric antibiotic therapy in patients 
with  cholangitis.  Amikacin,  Netilmycin  or  Piperacillin  /  Tazobactum  is 
recommended as initial empiric therapy to cover gram negative organisms and 
Ampicillin or high dose Gentamycin for gram positive organisms.  Carbapenams 
for gram negative organisms, and Teicoplanin or Vancomycin for gram positive 
organisms should be reserved for patients resistant to first line therapy to prevent 
development of resistance.
9. Naso-biliary drainage  and stenting for biliary decompression in patients of acute 
cholangitis are equally effective
10.  Stone disease is more common in patients from southern region   and malignant 
cause of biliary obstruction is more common in eastern region reflecting referral 
patterns from East  India.
11.  The microbiological profile and treatment outcomes are similar in 
  patients with cholangitis due to benign and malignant  obstruction. 
12. Several   risk factors were identified in previous studies to  predict mortality in 
patients with acute cholangitis. The present  study showed  only ICU care  to be 
significantly  associated  with  mortality.  Further  studies  with  large  sample  size 
need to be performed to evaluate risk factors that predict mortality.
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PROFORMA
Sl No:                              DOA: DOD:
Name: Age:
Sex: 1) Male  2) Female Hos No:
State of origin:1) TN , 2) AP , 3) KL , 4) KT , 5) WB ,6) BIHAR , 7) Others(mention 
names)
Occupation:
Phone No:
Final Diagnosis:
History
1) Pain : Yes(1- mild, 2-moderate,3- severe) , 4-No                Duration: 
2) Fever: Yes (1- low grade, 2-moderate, 3-highgrade) , 4-No Duration
3) Chills : 1- yes , 2- No
4) Jaundice: 1- Yes , 2- No               Duration
5) Cholestatic symptoms: 1) yes (pale stools, pruritus), 2)  No
6) Wt loss:  yes (1- mild, 2- moderate, 3- severe) , 4-No
7) Anorexia:1-Yes, 2- No
8) Altered bowel habits: ( Diarrohea , Constipation) 1- yes, 2-No
9) GI bleed: 1-Hematemesis, 2- Melena, 3- haematochazia, 4-No
10) Others:
Past history          
Surgery:  1-yes ( nature of sx) ,2-No
Biliary colic: 1- yes, 2-No
Jaundice: 1-yes,2-No
H/O ERCP: 1- yes, (Indication),2-No
DM: 1- yes, 2-No
TB: 1-yes, 2-No
HTN: 1- yes, 2-No
IHD: 1-yes, 2-No
Personal History
Alcohol: 1- yes (Duration , Amount), 2-No
Smoking: 1- yes ( Duration, No of cig/bidis per day, pack per year),2-No
High risk behaviour:1- yes, 2- no
Family History:
On Examination
Pallor: y/n               Icterus:y/n                 Lymphnode:pos/neg        Clubbing:pres/abs 
Edema:pres/abs              sensorium: norm/alttered              
Nails:nor/abnorm      scratch marks: pres/abs                 
Oral cavity: norm/abnor            Eye: norm/abnorm
Signs of livercell failure:pres/abs
BP:             Pulse;                      Wt:                    Height:               BMI:
P/A: 1-tendernes,         2-  hepatomegaly,       3- palpable GB/mass,              4-  ascites 
P/R:
LAB  
Tests Date Date Date
Hb
TC
DC
Toxic changes
LFT
Crt
Na
K
BBVS
Stool parasites
Urine R/M
Blood 
C/S(aerobic)
Blood 
C/S(anerobic)
BileC/S(aerobic)
Bile 
C/S(anerobic)
CXR:
USG:
IHBRD : yes, (1- mild,2- moderate,3- severe), 4-No
Dilated CBD:1-Yes( cm), 2-No
GB stone: 1-yes, 2-No
Lesion: 1-stone, 2-stricture,3-malignancy, 4-others, 5-none
MRI :
IHBRD : yes, (1- mild,2- moderate,3- severe), 4-No
Dilated CBD:1-Yes( cm), 2-No
GB stone: 1-yes, 2-No
Lesion: 1-stone, 2-stricture,3-malignancy, 4-others, 5-none
EUS:
IHBRD : yes, (1- mild,2- moderate,3- severe), 4-No
Dilated CBD:1-Yes( cm), 2-No
GB stone: 1-yes, 2-No
Lesion: 1-stone, 2-stricture,3-malignancy, 4-others, 5-none
CT:
 IHBRD : yes, (1- mild,2- moderate,3- severe), 4-No
Dilated CBD:1-Yes( cm), 2-No
GB stone: 1-yes, 2-No
Lesion: 1-stone, 2-stricture,3-malignancy, 4-others, 5-none
ERCP(Cholangiogram): 1-stone,2- stricture,3-malignancy, 4-choledochal cyst, 5-normal
Treatment
ICU care: 1-yes(duration), 2-No
Duration of hospitalisation:
Interval between onset of symptom and intervention(ERCP/PTBD/ Surgery):
Intervention:1-ERCP/2-PTBD/3-Surgery/4-Antibiotics
Antibiotic received:Details(Dose/ Duration)
Status at discharge:1-sick,2- healthy, 3-death
PATIENT CONSENT FORM
Patient Hospital Number: -------------------------------------------------
Name of Researcher: -------------------------------------------------
It has been explained clearly to me in a language that I understand.
1. That a research study on bacteriological profile and antibiotic sensitivity in acute 
cholangitis is being conducted in the Department of GI Sciences, CMCH, Vellore.
2. I  understand  that  taking part  in  this  study  is  voluntary  and that  I  am free  to 
withdraw at any time, without any reason and doing so will not affect my medical 
and legal rights.
3. I  understand  that  some  of  my  medical  notes  will  need  to  be  looked  at  by 
responsible  indivisuals  from  Christian  Medical  College,  Vellore  where  the 
treatment is to be carriedout.I give permission for these indivisuals to have access 
to my records.
4. I hereby give my full consent to take part in the study.
Name of the Patient: __________________________           
Tel.No.: ____________ 
Address: ___________________________
     ___________________________
Signature:____________________           Date:______________
Name of Witness: ______________          Date:______________
Two copies of this are needed. One to be kept with the patients study file and the 
another to be given to the patient   
